Aminoadamantane derivatives as therapeutic agents

Details Aminoadamantane derivatives as therapeutic agents Aminoadamantane derivatives as therapeutic agents

2002-07-19

2003-09-16

Criares, Theodore J. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S617000, C514S619000, C514S626000, C514S629000, C514S656000, C514S662000

Reexamination Certificate

active

06620845

ABSTRACT:

BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et al.,
J. Am. Med. Assoc.
(1969) 208:1168). Another derivative, memantine, is currently under clinical investigation for the treatment of various neurodegenerative diseases and has been licensed for the treatment of Parkinson's associated spasticity in Germany (Schneider et al.,
Dtsch. Med. Wschr.
(1984) 109:987).
Memantine protects cortical and retinal neuron cultures from the toxicity of glutamate, NMDA and the HIV-1 coat protein gp120 (Dreyer et al.,
Science
(1990) 248:364). Recent studies demonstrate that it prevents quinolinic acid-induced hippocampal damage in rats (Kelhoff and Wolf.,
Eur. J. Pharmacol.
(1992) 219:451). Memantine demonstrates antiphypoxic properties in vitro and in vivo. It is thought that memantine exerts a neuroprotective effect because it is a micromolar antagonist of the NMDA receptor (Bormann J.,
Eur. J. Pharmacol.
(1989) 166:591).
While memantine is being used to treat neurological disorders, the variety and severity of neurological diseases presents a need for other neuroprotective agents. The present invention provides novel compounds, compositions and methods for the treatment of neurological diseases. The present invention also provides methods of making the novel compounds.
SUMMARY OF THE INVENTION
The present invention provides compounds that can be used in the treatment of neurological diseases. The compounds are of the following formula or pharmaceutically acceptable salts thereof:
The groups R
1
, R
2
, R
3
, R
4
and R
5
of the formula are independently defined. R
1
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)
6
. R
2
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
3
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
4
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
5
is OR
7
, alkyl-OR
7
or heteroalkyl-OR
7
. R
6
is alkyl, heteroalkyl, aryl or heteroaryl. R
7
is NO
2
, C(O)R
6
, C(O)alkyl-ONO
2
or C(O)heteroalkyl-ONO
2
. The following substituents are preferred: R
1
and R
2
are H; R
3
and R
4
are H or alkyl; and, R
7
is NO
2
or C(O)alkyl-ONO
2
.
The present invention also provides pharmaceutical compositions that can be used to treat a neurological disorder. The compositions include a pharmaceutically acceptable carrier and one or more compounds of the following formula or pharmaceutically acceptable salts thereof:
The substituents of the compounds are independently defined. R
1
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
2
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
3
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
4
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
5
is OR
7
, alkyl-OR
7
or heteroalkyl-OR
7
. R
6
is alkyl, heteroalkyl, aryl or heteroaryl. R
7
is NO
2
, C(O)R
6
, C(O)alkyl-ONO
2
or C(O)heteroalkyl-ONO
2
. The following substituents are preferred: R
1
and R
2
are H; R
3
and R
4
are H or alkyl; and, R
7
is NO
2
or C(O)alkyl-ONO
2
.
The present invention also provides methods of treating a neurological disorder. The methods include administering to a patient a pharmaceutically acceptable carrier and one or more compounds of the following formula, or pharmaceutically acceptable salts thereof:
The substituents of the compounds are independently defined. R
1
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
2
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
3
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
4
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
5
is OR
7
, alkyl-OR
7
or heteroalkyl-OR
7
. R
6
is alkyl, heteroalkyl, aryl or heteroaryl. R
7
is NO
2
, C(O)R
6
, C(O)alkyl-ONO
2
or C(O)heteroalkyl-ONO
2
. The following substituents are preferred: R
1
and R
2
are H; R
3
and R
4
are H or alkyl; and, R
7
is NO
2
or C(O)alkyl-ONO
2
.
The present invention further provides methods of making compounds of the following formula or pharmaceutically acceptable salts thereof:
The substituents of the compounds are independently defined. R
1
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
2
is H, alkyl, heteroalkyl, aryl, heteroaryl, C(O)OR
6
or C(O)R
6
. R
3
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
4
is H, alkyl, heteroalkyl, aryl or heteroaryl. R
5
is OR
7
, alkyl-OR
7
or heteroalkyl-OR
7
. R
6
is alkyl, heteroalkyl, aryl or heteroaryl. R
7
is NO
2
, C(O)R
6
, C(O)alkyl-ONO
2
or C(O)heteroalkyl-ONO
2
. The following substituents are preferred: R
1
and R
2
are H; R
3
and R
4
are H or alkyl; and, R
7
is NO
2
or C(O)alkyl-ONO
2
.
Preferably, the methods involve oxidizing a compound of the following formula:
Preferably, the methods further involve nitrating a compound of the formula:
Preferably, the compound is treated with H
2
SO
4
and water in the oxidation step. The nitration step preferably includes treatment with HNO
3
and Ac
2
O.


REFERENCES:
patent: 6444702 (2002-09-01), Wang et al.

Affiliated with

Also associated with

Rating

Aminoadamantane derivatives as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aminoadamantane derivatives as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoadamantane derivatives as therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3050319